logo-loader
viewGenprex, Inc.

Genprex receives $2.5 million from warrant exercises as it moves towards clinical trials

The funds bring the equity capital raised by the group during 2020 to roughly $28 million, putting it in a “strong position” to pursue a planned clinical trial of its Oncoprex immunogene therapy candidate

Genprex, Inc. - Genprex receives $2.5 million from warrant exercises
Genprex said the warrant exercise was a “significant milestone” for the firm

Genprex Inc (NASDAQ:GNPX) said it has received $2.5 million in cash after warrants were exercised at $0.46 per share to purchase approximately 5.4 million shares issued in connection with capital raises in May 2018 and November 2019 by two institutional investors.

The company said the warrants exercised accounted for around 70% of its overall outstanding warrants and the exercise of such a large amount was a “significant milestone” in that it provided a “dramatically simplified capital structure”.

READ: Genprex shares rise after Noble Capital Markets repeats Outperform rating, $5 price target

The additional funds bring the equity capital raised by the group during 2020 to roughly $28 million, with Genprex saying it is in a “strong position” to pursue a planned clinical trial of its lead gene therapy drug candidate, Oncoprex immunogene therapy in combination with AstraZeneca PLC's targeted therapy Tagrisso in non-small cell lung cancer (NSCLC) patients, for which the company was granted United States FDA Fast Track Designation in January.

The firm is also planning a clinical trial of Oncoprex combined with Keytruda - marketed by Merck - for late-stage NSCLC.

Genprex is focused on developing potentially life-changing technologies for patients with cancer and diabetes.

Contact the author at [email protected]

Follow him on Twitter @Cal_Proac

Quick facts: Genprex, Inc.

Price: 2.96 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $114.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

1 week, 5 days ago

2 min read